ARCT
Price
$19.48
Change
+$0.25 (+1.30%)
Updated
Aug 15 closing price
Capitalization
528.97M
81 days until earnings call
CLDX
Price
$25.50
Change
+$0.56 (+2.25%)
Updated
Aug 15 closing price
Capitalization
1.69B
81 days until earnings call
Interact to see
Advertisement

ARCT vs CLDX

Header iconARCT vs CLDX Comparison
Open Charts ARCT vs CLDXBanner chart's image
Arcturus Therapeutics Holdings
Price$19.48
Change+$0.25 (+1.30%)
Volume$994.18K
Capitalization528.97M
Celldex Therapeutics
Price$25.50
Change+$0.56 (+2.25%)
Volume$1.4M
Capitalization1.69B
ARCT vs CLDX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. CLDX commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ARCT: $19.48 vs. CLDX: $25.50)
Brand notoriety: ARCT and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 173% vs. CLDX: 128%
Market capitalization -- ARCT: $528.97M vs. CLDX: $1.69B
ARCT [@Biotechnology] is valued at $528.97M. CLDX’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while CLDX’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 4 bearish.
  • CLDX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ARCT and CLDX are a good buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а +63.56% price change this week, while CLDX (@Biotechnology) price change was +23.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

CLDX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.69B) has a higher market cap than ARCT($529M). ARCT YTD gains are higher at: 14.791 vs. CLDX (0.910). ARCT has higher annual earnings (EBITDA): -63.92M vs. CLDX (-213.94M). CLDX has more cash in the bank: 673M vs. ARCT (217M). CLDX has less debt than ARCT: CLDX (3.43M) vs ARCT (42.7M). ARCT has higher revenues than CLDX: ARCT (131M) vs CLDX (7.56M).
ARCTCLDXARCT / CLDX
Capitalization529M1.69B31%
EBITDA-63.92M-213.94M30%
Gain YTD14.7910.9101,625%
P/E RatioN/AN/A-
Revenue131M7.56M1,733%
Total Cash217M673M32%
Total Debt42.7M3.43M1,246%
FUNDAMENTALS RATINGS
ARCT vs CLDX: Fundamental Ratings
ARCT
CLDX
OUTLOOK RATING
1..100
8366
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
3848
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
4750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (46) in the Pharmaceuticals Major industry is in the same range as CLDX (62) in the Biotechnology industry. This means that ARCT’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that CLDX’s stock grew similarly to ARCT’s over the last 12 months.

CLDX's SMR Rating (95) in the Biotechnology industry is in the same range as ARCT (95) in the Pharmaceuticals Major industry. This means that CLDX’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as CLDX (48) in the Biotechnology industry. This means that ARCT’s stock grew similarly to CLDX’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CLDX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCLDX
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ODVNX41.98N/A
N/A
Invesco Developing Markets R
WRAAX13.78N/A
N/A
Wilmington Global Alpha Equities A
EKWDX98.21N/A
N/A
Allspring Precious Metals Admin
DNREX13.26N/A
N/A
Dunham Real Estate Stock N
DDZRX14.28-0.06
-0.42%
Macquarie Value R6

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CLDX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+1.30%
CLDX - ARCT
51%
Loosely correlated
+2.25%
RGNX - ARCT
51%
Loosely correlated
-2.65%
RXRX - ARCT
51%
Loosely correlated
+2.30%
BEAM - ARCT
51%
Loosely correlated
+1.08%
PDSB - ARCT
49%
Loosely correlated
-0.83%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+2.25%
DNLI - CLDX
52%
Loosely correlated
+1.66%
CRNX - CLDX
51%
Loosely correlated
+3.47%
RVMD - CLDX
51%
Loosely correlated
+0.83%
BEAM - CLDX
50%
Loosely correlated
+1.08%
IDYA - CLDX
50%
Loosely correlated
-0.16%
More